spot_img

about fansalaran

FanSalaran is a comprehensive media platform dedicated to reporting and clarifying the significant achievements of pharmaceutical companies. In collaboration with passionate and motivated young journalists, this website consistently strives to showcase the country's successes in order to inspire and encourage the hardworking individuals of this land.

Artificial Joints Market Sets New Record, Projected at USD 31.8 billion by 2032 | CAGR Of 4.6%

An artificial joint is a prosthesis or prosthetic joint, made of plastic, ceramic or metal, which is implanted to replace a damaged or diseased natural joint. The surgical procedure for implanting an artificial joint involves removal of the damaged or diseased joint of knee, hip, shoulder, and other joints. After removal of damaged part, surgeon replaces it with the prosthetic joint. The artificial joint mimics the natural movement of the original joint, allowing for improved mobility and pain reduction.

Allied Market Research published a report, titled, ”Artificial Joints Market by Type (Cemented Artificial Joints and Non-cemented Artificial Joints), Application (Artificial Knee Joints, Artificial Hip Joints, and Others), Material (Ceramics, Alloy, and Others), and End User (Hospitals and Others): Global Opportunity Analysis and Industry Forecast, 2023-2032.” According to the report, the global artificial Joints industry was valued at USD 20.2 billion in 2022 and is projected to reach USD 31.8 billion by 2032, registering a CAGR of 4.6% from 2023 to 2032.

The report provides a detailed analysis of the top investment pockets, top winning strategies, drivers & opportunities, market size & estimations, competitive landscape, and evolving market trends. The market study is a helpful source of information for the frontrunners, new entrants, investors, and shareholders in crafting strategies for the future and heightening their position in the market.

Hot this week

Daewoong Pharmaceutical Holds Talks with Saudi Officials on Bioindustry Cooperation

Daewoong Pharmaceutical said on October 17 that it met...

Novo Nordisk chair and independent directors to exit in strategy dispute

The chair of Wegovy maker Novo Nordisk and six...

Hologic to go private in up to $18.3 billion deal backed by Blackstone, TPG

Medical diagnostics firm Hologic has agreed to be acquired...

China’s Innovent signs $11.4 billion cancer therapy deal with Japan’s Takeda

-China’s Innovent Biologics said on Wednesday it had signed...

Topics

spot_img

Related Articles

Popular Categories

spot_imgspot_img